View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 19, 2022

Eisai enrols first patient in Phase II/III Alzheimer’s disease antibody trial

DIAN-TU selected E2814 as the first investigational therapy for the trial analysing anti-tau drugs in March last year.

Eisai has enrolled the first subject in the Phase II/III Tau NexGen clinical trial of its investigational anti-microtubule binding region (MTBR) tau antibody, E2814, for dominantly inherited Alzheimer’s disease (DIAD).

The patient was enrolled at Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) led by Washington University School of Medicine in St Louis.

Eisai created E2814 through a research partnership with University College London. 

Currently being developed as a disease altering agent for tauopathies such as sporadic AD, the MTBR tau antibody can potentially avert the tau seed spread within the brains of affected individuals.

The Tau NexGen trial will analyse the tolerability, safety, biomarker, and cognitive efficacy of investigational treatments in pre-symptomatic or symptomatic subjects with an AD-causing gene mutation. 

DIAN-TU chose E2814 as the first investigational therapy among anti-tau drugs for the trial in March last year.

Symptomatic subjects will be given anti-amyloid β (Aβ) protofibril antibody lecanemab for a duration of six months and randomised to receive the anti-tau drug or a placebo. 

As amyloid plaques deposit before tau tangles in AD, the trial design permits the researchers to determine whether removal of amyloid clears the way for the efficient functioning of the anti-tau drug.

On obtaining positive data in the primary and secondary endpoints in the assessment two years following trial commencement, the study will be expanded for additional two years to evaluate if the drug can decelerate cognitive decline and has an added impact on tau pathology.

Individuals with DIAD genetic mutations could develop AD and also have chances of developing symptoms at nearly the same age as their affected parents did. 

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU